531633 Stock Overview Engages in manufacturing and trading of pharmaceutical products in India. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Lincoln Pharmaceuticals Limited Competitors Price History & Performance
Summary of share price highs, lows and changes for Lincoln Pharmaceuticals Historical stock prices Current Share Price ₹771.75 52 Week High ₹975.00 52 Week Low ₹498.00 Beta 0.65 1 Month Change 21.62% 3 Month Change 13.75% 1 Year Change 26.69% 3 Year Change 115.63% 5 Year Change 272.02% Change since IPO 3,115.63%
Recent News & Updates
New major risk - Share price stability Dec 04
Investor sentiment improves as stock rises 20% Dec 03
Second quarter 2025 earnings released: EPS: ₹13.15 (vs ₹13.81 in 2Q 2024) Nov 15
Lincoln Pharmaceuticals Limited to Report Q2, 2025 Results on Nov 14, 2024 Nov 05
Lincoln Pharmaceuticals Limited Declarers Dividend for the Financial Year 2023-2024 Oct 03
Dividend increased to ₹1.80 Aug 31 See more updates
New major risk - Share price stability Dec 04
Investor sentiment improves as stock rises 20% Dec 03
Second quarter 2025 earnings released: EPS: ₹13.15 (vs ₹13.81 in 2Q 2024) Nov 15
Lincoln Pharmaceuticals Limited to Report Q2, 2025 Results on Nov 14, 2024 Nov 05
Lincoln Pharmaceuticals Limited Declarers Dividend for the Financial Year 2023-2024 Oct 03
Dividend increased to ₹1.80 Aug 31
Lincoln Pharmaceuticals Limited, Annual General Meeting, Sep 30, 2024 Aug 29
Lincoln Pharmaceuticals Limited, Annual General Meeting, Sep 30, 2024 Aug 28
First quarter 2025 earnings released: EPS: ₹11.82 (vs ₹9.49 in 1Q 2024) Aug 09
Lincoln Pharmaceuticals Limited to Report Q1, 2025 Results on Aug 08, 2024 Jul 31
Lincoln Pharmaceuticals Limited to Report Q1, 2024 Results on Aug 08, 2024 Jul 30
Whole Time Director recently bought ₹20m worth of stock Jun 06
Full year 2024 earnings released: EPS: ₹46.58 (vs ₹36.40 in FY 2023) May 17 Lincoln Pharmaceuticals Limited Recommends Dividend for the Year Ended March 31, 2024 May 17
Now 20% overvalued May 14
Now 22% overvalued Apr 22
Now 24% overvalued Mar 20
Lincoln Pharmaceuticals Limited Announces Resignation of Meha Patel as Non-Executive Independent women Director Feb 22
Insider recently bought ₹13m worth of stock Feb 20
Third quarter 2024 earnings released: EPS: ₹14.00 (vs ₹10.79 in 3Q 2023) Feb 09
Lincoln Pharmaceuticals Limited to Report Q3, 2024 Results on Feb 08, 2024 Jan 26
Second quarter 2024 earnings released: EPS: ₹13.81 (vs ₹11.84 in 2Q 2023) Nov 03
Lincoln Pharmaceuticals Limited Declares Dividend for the Financial Year 2022-23 Oct 01
Upcoming dividend of ₹1.50 per share at 0.3% yield Sep 08 Lincoln Pharmaceuticals Limited to Report Q3, 2024 Results on Feb 14, 2024
Whole Time Director recently bought ₹15m worth of stock Aug 25
First quarter 2024 earnings released: EPS: ₹9.49 (vs ₹7.49 in 1Q 2023) Aug 11
First quarter 2024 earnings released: EPS: ₹9.49 (vs ₹7.49 in 1Q 2023) Aug 11
Whole Time Director recently bought ₹15m worth of stock Jun 11
Full year 2023 earnings released: EPS: ₹36.40 (vs ₹34.63 in FY 2022) May 26 Lincoln Pharmaceuticals Limited Approves the Resignation of Anand A. Patel from the Position of Whole Time Director as Well as Director of the Company
Lincoln Pharmaceuticals Limited to Report Q4, 2023 Results on May 25, 2023 May 17
Whole Time Director recently bought ₹5.0m worth of stock Mar 08
Third quarter 2023 earnings released: EPS: ₹10.79 (vs ₹8.79 in 3Q 2022) Feb 10
Lincoln Pharmaceuticals Limited to Report Q3, 2023 Results on Feb 09, 2023 Feb 01
Lincoln Pharmaceuticals Limited Informs About Demise of Shri Ishwarlal Ambalal Patel Independent Director Dec 07
MD & Whole Time Director recently bought ₹20m worth of stock Dec 02
MD & Whole Time Director recently bought ₹9.9m worth of stock Nov 20
Less than half of directors are independent Nov 16
Lincoln Pharmaceuticals Limited Appoints Trusha Shah as Company Secretary and Compliance Officer Nov 10
Lincoln Pharmaceuticals Limited Approves to Declare Dividend for the Financial Year 2021-22 Oct 01
Upcoming dividend of ₹1.50 per share Sep 08
Lincoln Pharmaceuticals Limited Proposes to Declare Dividend for the Financial Year 2021-2022 Sep 07
Lincoln Pharmaceuticals Limited Proposes to Declare Dividend for the Financial Year 2021-2022 Sep 06
Lincoln Pharmaceuticals Limited, Annual General Meeting, Sep 30, 2022 Aug 27
Lincoln Pharmaceuticals Limited Approves Appointment of Anand A. Patel as an Additional and Whole Time Director Aug 10
First quarter 2023 earnings released: EPS: ₹7.49 (vs ₹8.85 in 1Q 2022) Aug 10
Lincoln Pharmaceuticals Limited to Report Q1, 2023 Results on Aug 09, 2022 Jul 30
Lincoln Pharmaceuticals Limited Announces Resignation of Niren A. Desai as Company Secretary / Compliance Officer, with Effect from July 19, 2022 Jul 21
Board Member recently bought ₹20m worth of stock Jun 09
Whole Time Director recently bought ₹20m worth of stock May 29
Full year 2022 earnings: EPS and revenues exceed analyst expectations May 24
Lincoln Pharmaceuticals Limited Recommends Dividend for the Year Ended March 31, 2022 May 20
Less than half of directors are independent Apr 27
Whole Time Director recently bought ₹6.0m worth of stock Feb 28
Third quarter 2022 earnings: EPS and revenues exceed analyst expectations Feb 13
Lincoln Pharmaceuticals Limited to Report Q3, 2022 Results on Feb 10, 2022 Feb 03
Board Member recently bought ₹8.2m worth of stock Nov 22
Lincoln Pharmaceuticals Limited (BSE:531633) acquired plant in Mehsana, Gujarat for INR 300 million. Sep 23
MD & Whole Time Director recently bought ₹15m worth of stock Sep 23
Investor sentiment improved over the past week Sep 09
Board Member recently bought ₹11m worth of stock Aug 28
Whole Time Director recently bought ₹12m worth of stock Aug 18
First quarter 2022 earnings released: EPS ₹8.85 (vs ₹7.63 in 1Q 2021) Aug 11
Whole Time Director recently bought ₹16m worth of stock Jun 18
Full year 2021 earnings released: EPS ₹31.11 (vs ₹25.72 in FY 2020) May 27
Lincoln Pharmaceuticals Limited Recommends Dividend for the Year Ended March 31, 2021 May 26
New 90-day high: ₹250 Mar 10
Whole Time Director recently bought ₹8.3m worth of stock Feb 22
Whole Time Director recently bought ₹30m worth of stock Feb 12
New 90-day low: ₹216 Feb 08
Third quarter 2021 earnings released: EPS ₹6.74 (vs ₹5.46 in 3Q 2020) Feb 03
Whole Time Director recently bought ₹20m worth of stock Jan 06
Second quarter 2021 earnings released: EPS ₹10.46 Nov 04
Revenue and earnings beat expectations Nov 04
Lincoln Pharmaceuticals Limited (BSE:531633) agreed to acquire remaining 1.42% stake in Lincoln Parenteral Limited for INR 3.7 million. Sep 22
New 90-day high: ₹256 Sep 16
Lincoln Pharmaceuticals Limited Launches Chewable Vitamin C + Zinc Tablet for the Markets in India Sep 14 Lincoln Pharmaceuticals Limited to Report Q4, 2021 Results on May 30, 2021
MD & Whole Time Director recently bought ₹2.4m worth of stock Aug 31
New 90-day high - ₹245 Aug 21
First quarter earnings released Aug 21
Lincoln Pharmaceuticals Limited to Report Q1, 2021 Results on Aug 20, 2020 Aug 14
New 90-day high - ₹208 Aug 03 Shareholder Returns 531633 IN Pharmaceuticals IN Market 7D -4.9% -0.7% -1.8% 1Y 26.7% 37.7% 17.5%
See full shareholder returns
Return vs Market: 531633 exceeded the Indian Market which returned 17.5% over the past year.
Price Volatility Is 531633's price volatile compared to industry and market? 531633 volatility 531633 Average Weekly Movement 9.3% Pharmaceuticals Industry Average Movement 6.0% Market Average Movement 6.2% 10% most volatile stocks in IN Market 9.1% 10% least volatile stocks in IN Market 4.1%
Stable Share Price: 531633's share price has been volatile over the past 3 months compared to the Indian market.
Volatility Over Time: 531633's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Indian stocks.
About the Company Lincoln Pharmaceuticals Limited engages in manufacturing and trading of pharmaceutical products in India. The company offers products in the areas of anticold, antibiotic, otolaryngology, pain management, gastro, anti-malarial, anti-fungal, corticosteroids and cosmo-derma, anti-diabetic, anti-hypertensive, gynecology, cardio and CNS, respiratory system, and dyslipidemic; and branded generics. It also exports its products to approximately 60 countries, including Europe, Canada, Latin and North America, Africa, the Asia Pacific, and South East Asia.
Show more Lincoln Pharmaceuticals Limited Fundamentals Summary How do Lincoln Pharmaceuticals's earnings and revenue compare to its market cap? 531633 fundamental statistics Market cap ₹15.46b Earnings (TTM ) ₹966.39m Revenue (TTM ) ₹5.97b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 531633 income statement (TTM ) Revenue ₹5.97b Cost of Revenue ₹2.87b Gross Profit ₹3.10b Other Expenses ₹2.13b Earnings ₹966.39m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) 48.25 Gross Margin 51.90% Net Profit Margin 16.18% Debt/Equity Ratio 0.2%
How did 531633 perform over the long term?
See historical performance and comparison Dividends
0.2% Current Dividend Yield
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/27 20:30 End of Day Share Price 2024/12/27 00:00 Earnings 2024/09/30 Annual Earnings 2024/03/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Lincoln Pharmaceuticals Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Kameswari V. S. Chavali FirstCall Research
Show 0 more analysts 
